Gemigliptin/Dapagliflozin is contraindicated in patients with/on: hypersensitivity to the active substances or to any of the excipients listed in Description, or a history of serious hypersensitivity reactions, i.e., angioedema or anaphylaxis, to another dipeptidyl peptidase-4 (DPP-4) inhibitor or sodium glucose cotransporter (SGLT) 2 inhibitor (see Precautions); type 1 diabetes or diabetic ketoacidosis; rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption; hemodialysis.